ABCL

Abcellera Biologics Inc

ABCL, USA

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

https://www.abcellera.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ABCL
stock
ABCL

AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen MarketBeat

Read more →
ABCL
stock
ABCL

Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$9.8333

Analyst Picks

Strong Buy

6

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.29

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-5.92 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-4.21 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-687.01 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.41

Low 1

High 0.3

Investors

* Institutions hold a combined 46.52% of the total shares of Abcellera Biologics Inc

1.

Baker Bros Advisors LP

(9.211%)

since

2025/06/30

2.

Capital World Investors

(4.4711%)

since

2025/06/30

3.

American Funds SMALLCAP World A

(4.4711%)

since

2025/06/30

4.

Baillie Gifford & Co Limited.

(3.4668%)

since

2025/06/30

5.

UBS Asset Mgmt Americas Inc

(2.8349%)

since

2025/06/30

6.

SMDS Global AI Equity Mother

(1.5027%)

since

2025/03/25

7.

Two Sigma Investments LLC

(1.3756%)

since

2025/06/30

9.

Two Sigma Advisers, LLC

(1.3621%)

since

2025/06/30

10.

Baillie Gifford Positive Change B Acc

(1.3008%)

since

2025/07/31

11.

Baillie Gifford Positive Change

(1.3008%)

since

2025/07/31

12.

BlackRock Inc

(1.2317%)

since

2025/06/30

13.

UBS Group AG

(1.1538%)

since

2025/06/30

14.

UBS Lux Dgtl Hlth Eq Fd seeding P acc

(1.1385%)

since

2025/07/31

15.

Millennium Management LLC

(1.137%)

since

2025/06/30

16.

Orbimed Advisors, LLC

(1.1192%)

since

2025/06/30

17.

Renaissance Technologies Corp

(1.1068%)

since

2025/06/30

18.

Citadel Advisors Llc

(0.967%)

since

2025/06/30

19.

TANG CAPITAL MANAGEMENT LLC

(0.8701%)

since

2025/06/30

20.

Baillie Gifford WW Pstv Chg B USD Acc

(0.755%)

since

2025/07/31

21.

ACATIS Datini Valueflex Fonds A

(0.6224%)

since

2025/07/31

22.

Guardian Partners Inc.

(0.5978%)

since

2025/06/30

23.

iShares Biotechnology ETF

(0.4486%)

since

2025/08/31

24.

Morgan Stanley - Brokerage Accounts

(0.3336%)

since

2025/06/30

25.

Novo A/S

(0.2184%)

since

2025/06/30

26.

NORGES BANK

(0.2111%)

since

2025/06/30

27.

State Street Corp

(0.2056%)

since

2025/06/30

28.

Susquehanna International Group, LLP

(0.1989%)

since

2025/06/30

29.

iShares Genomics Immnlgy & Hlthcr ETF

(0.1867%)

since

2025/08/31

30.

SPDR® Portfolio Developed Wld ex-US ETF

(0.167%)

since

2025/08/29

31.

Lazard Digital Health

(0.1589%)

since

2025/06/30

32.

Baillie Gifford Positive Chg CI FD Cl E

(0.1545%)

since

2025/06/30

33.

Keystone Positive Change Investment Ord

(0.1352%)

since

2025/02/28

34.

Vanguard Baillie GiffordGlbPstvImpStkInv

(0.1343%)

since

2025/06/30

35.

Desjardins Sustainable Positive Change F

(0.1272%)

since

2025/08/31

36.

BlackRock Advantage Small Cap Core Instl

(0.1161%)

since

2025/07/31

37.

SEB Artificial Intelligence D (USD)

(0.1139%)

since

2025/07/31

38.

iShares Healthcare Innov ETF USD Acc

(0.0869%)

since

2025/08/31

39.

Fidelity Nasdaq Composite ETF

(0.0772%)

since

2025/08/29

40.

DNB Fund - Disruptive Opp Retail A EUR

(0.0744%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.144

Latest Release

Date

2025-09-30

EPS Actual

-0.19

EPS Estimate

-0.14

EPS Difference

-0.05

Surprise Percent

-35.7143%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.